BioSpace News Archive

Drug Development

AbbVie’s ‘s Imbruvica Fails to Gain Traction in Pancreatic Cancer

The company provided an update on its Phase III trial of Imbruvica in combination with chemotherapy compared to placebo in metastatic pancreatic adenocarcinoma.

January 21, 2019
·
3 min read
·
Mark Terry
Deals

Amid Government Shutdown, Companies Try New Approaches to IPOs

Last year was a record year for biotech initial public offerings (IPOs), but 2019 is off to a slow and rocky start because of the government shutdown, which today is in its 31st day.

January 21, 2019
·
3 min read
·
Mark Terry
Business

Interview: Opiant Focuses R&D Efforts on Battling Addiction and Overdoses

As Purdue Pharmaceutical’s OxyContin has become the poster child for opioid addiction, so too has another drug become synonymous with efforts to save people who have overdosed on those drugs – Narcan, developed by California-based Opiant Pharmaceuticals.

January 21, 2019
·
4 min read
·
Alex Keown
Drug Development

BerGenBio Announces Start of Phase I Trial Evaluating ADCT-601, a Novel Anti-AXL ADC, in Patients With Advanced Solid Tumours

ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics for antibody drug conjugate (ADC) development

January 21, 2019
·
4 min read
Deals

Targovax is Invited to Present at Upcoming Investor Conferences

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management team will present at upcoming investor conferences.

January 21, 2019
·
1 min read
Policy

/R E P E A T -- Notice to the media - Minister of Health to unveil Canada’s new Food Guide/

The Honourable Ginette Petitpas Taylor, Minister of Health, will unveil Canada’s new Food Guide on Tuesday, January 22, 2019.

January 21, 2019
·
1 min read
Policy

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

Lumacaftor/ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 children aged 2 to 5 with two copies of the F508del mutation

January 21, 2019
·
5 min read
Business

Caris Life Sciences Names Chief Communications Officer

Caris Life Sciences® today announced that Srikant (Sri) Ramaswami, has joined the company as Vice President and Chief Communications Officer.

January 21, 2019
·
2 min read
European Update: Spectrum Cannabis enters UK & Poland

High-quality medical cannabis available today in Polish pharmacies; UK presence positions Spectrum to lead in a key emerging market.

January 21, 2019
·
8 min read
BioMidwest

HNC Virtual Solutions Develops Technology-Enabled Solution to Combat Current Opioid Crisis

Video and Consumer Platform and Kiosks Aim to Improve Patient Rehabilitation Rates

January 21, 2019
·
3 min read